The Advisory Board Co. (NASDAQ:ABCO) shares gapped up prior to trading on Tuesday . The stock had previously closed at $37.64, but opened at $38.09. The Advisory Board shares last traded at $39.51, with a volume of 118,190 shares.

Several research firms recently issued reports on ABCO. Canaccord Genuity reissued a “buy” rating on shares of The Advisory Board in a research report on Sunday, May 29th. KeyCorp reissued a “hold” rating on shares of The Advisory Board in a research report on Sunday, May 22nd. FBR & Co reissued a “hold” rating on shares of The Advisory Board in a research report on Sunday, May 8th. Robert W. Baird reissued a “hold” rating on shares of The Advisory Board in a research report on Sunday, May 8th. Finally, Zacks Investment Research lowered shares of The Advisory Board from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Seven analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $40.47.

The stock’s 50-day moving average price is $34.53 and its 200 day moving average price is $35.60. The firm’s market cap is $1.61 billion.

The Advisory Board (NASDAQ:ABCO) last posted its quarterly earnings data on Thursday, May 5th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.07. The business earned $200.70 million during the quarter, compared to the consensus estimate of $201.74 million. During the same period in the prior year, the firm earned $0.30 EPS. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities analysts predict that The Advisory Board Co. will post $1.71 EPS for the current year.

In other news, Director Kelt Kindick purchased 5,000 shares of the business’s stock in a transaction dated Tuesday, May 31st. The stock was bought at an average price of $32.81 per share, with a total value of $164,050.00. Following the acquisition, the director now owns 22,662 shares in the company, valued at approximately $743,540.22. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Cormac F. Miller sold 1,628 shares of the company’s stock in a transaction that occurred on Thursday, April 14th. The stock was sold at an average price of $31.65, for a total transaction of $51,526.20. Following the sale, the insider now directly owns 15,571 shares of the company’s stock, valued at approximately $492,822.15. The disclosure for this sale can be found here.

Several hedge funds have recently modified their holdings of the company. GAM Holding AG increased its stake in shares of The Advisory Board by 137.2% in the fourth quarter. GAM Holding AG now owns 47,910 shares of the company’s stock worth $2,377,000 after buying an additional 27,710 shares during the period. Mutual of America Capital Management LLC increased its stake in shares of The Advisory Board by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 96,676 shares of the company’s stock worth $4,796,000 after buying an additional 577 shares during the period. Sei Investments Co. increased its stake in shares of The Advisory Board by 675.3% in the fourth quarter. Sei Investments Co. now owns 158,279 shares of the company’s stock worth $7,853,000 after buying an additional 137,865 shares during the period. American Capital Management Inc. increased its stake in shares of The Advisory Board by 24.9% in the fourth quarter. American Capital Management Inc. now owns 529,055 shares of the company’s stock worth $26,246,000 after buying an additional 105,360 shares during the period. Finally, Thornburg Investment Management Inc. increased its stake in shares of The Advisory Board by 13.6% in the fourth quarter. Thornburg Investment Management Inc. now owns 378,087 shares of the company’s stock worth $18,757,000 after buying an additional 45,194 shares during the period.

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.